Ionis Pharmaceuticals (IONS) Change in Accured Expenses (2013 - 2026)

Ionis Pharmaceuticals' Change in Accured Expenses history runs 14 years deep, the most recent figure standing at $21.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 148.8% year-over-year to $21.0 million; the TTM figure through Mar 2026 stood at $69.4 million (up 3898.5% YoY), while the FY2025 annual figure was $5.3 million, up 182.56% from the prior year.
• Change in Accured Expenses was $21.0 million for Q1 2026 at Ionis Pharmaceuticals, up from $17.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $52.1 million in Q3 2022 to a low of -$43.0 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $4.1 million across 5 years, with a median of $10.5 million in 2025.
• Biggest YoY gain for Change in Accured Expenses was 1229.4% in 2022; the steepest drop was 707.51% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at $8.4 million in 2022, then advanced by 17.3% to $9.9 million in 2023, then jumped by 208.85% to $30.5 million in 2024, then plunged by 41.32% to $17.9 million in 2025, then rose by 17.16% to $21.0 million in 2026.
• The last three Change in Accured Expenses figures came in at $21.0 million (Q1 2026), $17.9 million (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.